Inogen Inc (INGN) · Nov 19, 2026 · Exec change
CEO separation — $1.47M salary severance over 24 months; up to $610,026 target bonus
Inogen’s CEO separation agreement discloses $1.47 million in salary severance, a potential 2026 bonus, and limited equity acceleration.
Inogen is in the middle of a reset: it has exited its U.S. oxygen-rental business, launched a $20 million cost-reduction program, and is refocusing on respiratory-device sales and profitable growth under new CEO Andy Reding. The CEO transition itself was already disclosed on November 5, so this filing is mainly the financial and legal settlement behind Kevin Smith’s October 30 departure.
The filing puts a meaningful price tag on the leadership change. Inogen will pay Smith $1.4697 million over 24 months, continue certain health benefits, and leave him eligible for a performance-based 2026 bonus with a $610,026.16 target. 〔0〕 〔1〕
| Compensation item | Amount / date | Comparison |
|---|---|---|
| Salary severance (Consideration) | $1.4697M | 24 months |
| Monthly severance (Consideration) | $61,237.50 | 24 payments |
| 2026 bonus target (Consideration) | $610,026.16 | Payable by Mar. 15, 2027 |
| Equity acceleration (Equity Acceleration) | Scheduled Dec. 1, 2026 vesting | Settles Dec. 1, 2026 |
| Separation date (Recitals) | Oct. 30, 2026 | — |
The agreement also closes the door on future claims and ongoing company roles. Smith resigns from all officer, employee, and director positions, forfeits unvested equity except for awards scheduled to vest on December 1, and releases broad employment-related claims. 〔2〕 〔3〕 〔4〕
Relative to expectations, this is more detail than surprise. The departure and planned separation agreement were already announced, so the filing does not change who is running Inogen or its strategic direction. The new information is the sizable but contractual payout, which modestly adds to the cost of a transition already embedded in the company’s turnaround plan; the agreement also states Smith’s resignation was not due to disagreement with company operations or policies. 〔5〕
Bottom line: This filing formalizes an already-known CEO change and quantifies its cost rather than rewriting Inogen’s business story. It is modestly negative for the company because of the cash and compensation burden, but the main transition was already public and the agreement removes some uncertainty around the exit.
2027 annual meeting and continued turnaround execution
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!